Trials / Completed
CompletedNCT00483132
Study of Treatment High Risk and/or Low Risk Acute Lymphoblastic leukémia(ALL) Adults Stage III
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 232 (actual)
- Sponsor
- French Innovative Leukemia Organisation · Academic / Other
- Sex
- All
- Age
- 15 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Improved outcome of high risk lymphoblastic leukemia (ALL) with laite high dose therapy. High dose versus conventional therapy for adult low risk T-ALL and Lymphoblastic lymphoma (LBL).
Detailed description
Comparison between two autograf therapeutic strategies in high risk patients Ramdomised comparison between maintenance treatment with or not interferon alpha 2 a
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | interferon alpha 2a |
Timeline
- Start date
- 1994-09-01
- Completion
- 2002-04-01
- First posted
- 2007-06-06
- Last updated
- 2007-06-06
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT00483132. Inclusion in this directory is not an endorsement.